Click HERE to download the PDF

Moving investigational therapeutics to the clinic can be a challenging process and oligonucleotides are no different. There are numerous potential pitfalls to navigate throughout the journey from the bench to clinic.

The term oligonucleotide itself encompasses an array of compound types including double stranded siRNA, single stranded antisense, backbone and monomer changes such as phosphorothiolate linkages and conformationally constrained nucleotides, conjugates with molecules like GalNAc and a host of others.

In batch mode production scaling a process is fairly straightforward – use larger equipment. However, since oligos are produced via solid phase synthesis – this is not as straightforward. While it is obvious that upstream equipment requirement ... ...